Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation.
Tachibana T, Miyazaki T, Matsumura A, Hagihara M, Tanaka M, Koyama S, Ogusa E, Aoki J, Nakajima Y, Takahashi H, Suzuki T, Ishii Y, Teshigawara H, Matsumoto K, Hatayama M, Izumi A, Ikuta K, Yamamoto K, Kanamori H, Fujisawa S, Nakajima H. Tachibana T, et al. Among authors: miyazaki t. Cytotherapy. 2024 Mar 30:S1465-3249(24)00575-9. doi: 10.1016/j.jcyt.2024.03.490. Online ahead of print. Cytotherapy. 2024. PMID: 38625069
Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
Ando T, Fujisawa S, Teshigawara H, Matsumura A, Sakuma T, Suzuki T, Teranaka H, Ogusa E, Ishii Y, Miyashita K, Takahashi H, Nakajima Y, Miyazaki T, Hagihara M, Matsumoto K, Yamazaki E, Nakajima H. Ando T, et al. Among authors: miyazaki t. Int J Hematol. 2020 Jul;112(1):46-56. doi: 10.1007/s12185-020-02870-5. Epub 2020 May 25. Int J Hematol. 2020. PMID: 32451786
Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation.
Teshigawara-Tanabe H, Hagihara M, Aoki J, Koyama S, Takahashi H, Nakajima Y, Kunimoto H, Tachibana T, Miyazaki T, Matsumoto K, Tanaka M, Yamazaki E, Fujisawa S, Kanamori H, Taguri M, Nakajima H. Teshigawara-Tanabe H, et al. Among authors: miyazaki t. Hematology. 2022 Dec;27(1):620-628. doi: 10.1080/16078454.2022.2052601. Hematology. 2022. PMID: 35621915
Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.
Nukui J, Tachibana T, Miyazaki T, Tanaka M, Matsumoto K, Ishii Y, Numata A, Nakajima Y, Matsumura A, Suzuki T, Izumi A, Hirose N, Yamamoto K, Hagihara M, Fujisawa S, Kanamori H, Nakajima H. Nukui J, et al. Among authors: miyazaki t. Int J Hematol. 2024 Jan;119(1):62-70. doi: 10.1007/s12185-023-03688-7. Epub 2023 Dec 12. Int J Hematol. 2024. PMID: 38082200
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Among authors: miyazaki t. Int J Hematol. 2018 May;107(5):578-585. doi: 10.1007/s12185-017-2396-9. Epub 2018 Jan 5. Int J Hematol. 2018. PMID: 29305770 Clinical Trial.
Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
Tachibana T, Andou T, Tanaka M, Ito S, Miyazaki T, Ishii Y, Ogusa E, Koharazawa H, Takahashi H, Motohashi K, Aoki J, Nakajima Y, Matsumoto K, Hagihara M, Hashimoto C, Taguchi J, Fujimaki K, Fujita H, Fujisawa S, Kanamori H, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT). Tachibana T, et al. Among authors: miyazaki t. Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):415-421. doi: 10.1016/j.clml.2018.03.009. Epub 2018 Mar 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29673622
Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia.
Ando T, Fujisawa S, Teshigawara H, Ogusa E, Ishii Y, Miyashita K, Motohashi K, Miyazaki T, Tachibana T, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Koharazawa H, Fujimaki K, Taguchi J, Fujita H, Kanamori H, Yamazaki E, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT). Ando T, et al. Among authors: miyazaki t. Int J Hematol. 2019 Jun;109(6):673-683. doi: 10.1007/s12185-019-02647-5. Epub 2019 Apr 8. Int J Hematol. 2019. PMID: 30963469
Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A, Miyazaki T, Tachibana T, Ando T, Koyama M, Koyama S, Ishii Y, Takahashi H, Nakajima Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S, Nakajima H. Matsumura A, et al. Among authors: miyazaki t. Turk J Haematol. 2020 Feb 20;37(1):20-29. doi: 10.4274/tjh.galenos.2019.2019.0139. Epub 2019 Aug 29. Turk J Haematol. 2020. PMID: 31464120 Free PMC article.
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Among authors: miyazaki t. Transplant Cell Ther. 2021 Jan;27(1):70.e1-70.e8. doi: 10.1016/j.bbmt.2020.09.025. Epub 2020 Sep 30. Transplant Cell Ther. 2021. PMID: 33007494 Free article.
4,205 results